Related Experiment Videos
Inhibition of topoisomerases in African trypanosomes
1Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Abstract:
African trypanosomiasis continues to pose a challenge for the development of new chemotherapy. Type II topoisomerases, essential enzymes in nucleic acid metabolism, have proven highly suitable as targets for antibacterial and antitumor therapy. Well-characterized topoisomerase II inhibitors affect the cognate nuclear and mitochondrial enzymes in Trypanosoma equiperdum. Inhibition is accompanied by extensive fragmentation and structural alteration in nuclear and mitochondrial DNA. Some clinically important antitrypanosomal drugs bind to DNA (i.e., pentamidine, isometamidium, diminazene). These agents inhibit the mitochondrial, but not nuclear, topoisomerase II of trypanosomes. These studies suggest that type II topoisomerase inhibitors may prove to be effective and safe new antitrypanosomal drugs.
Insights
New chemotherapy for African trypanosomiasis is challenging. Targeting type II topoisomerases, which are essential enzymes, shows promise for developing effective and safe antitrypanosomal drugs.
Area of Science:
- Parasitology
- Molecular Biology
- Drug Discovery
Background:
- African trypanosomiasis remains a significant therapeutic challenge.
- Type II topoisomerases are crucial enzymes for DNA replication and are validated targets for antimicrobial and anticancer drugs.
Purpose of the Study:
- To investigate the efficacy of type II topoisomerase inhibitors as potential antitrypanosomal agents.
- To evaluate the impact of these inhibitors on the nuclear and mitochondrial DNA of Trypanosoma equiperdum.
Main Methods:
- Treatment of Trypanosoma equiperdum with known type II topoisomerase inhibitors.
- Analysis of nuclear and mitochondrial DNA for fragmentation and structural alterations post-treatment.
- Assessment of the inhibitory effects of clinically relevant antitrypanosomal drugs on trypanosomal topoisomerase II.
Main Results:
- Type II topoisomerase inhibitors effectively targeted both nuclear and mitochondrial enzymes in Trypanosoma equiperdum.
- Inhibition led to significant fragmentation and structural changes in both nuclear and mitochondrial DNA.
- Existing antitrypanosomal drugs like pentamidine inhibit mitochondrial topoisomerase II but not nuclear topoisomerase II.
Conclusions:
- Type II topoisomerases are viable targets for novel antitrypanosomal drug development.
- Inhibitors of type II topoisomerases demonstrate potential as effective and safe therapeutic agents against African trypanosomiasis.